stockrow
Saturday 7 November 2026
Export CRVS’s income statement to Excel — free account
Corvus Pharmaceuticals, Inc.
CRVS Healthcare Biotechnology
- EPS
- −90.0%
- Free cash flow
- −171.3%
Quarter to June 2026, against a year earlier
10.57
0.84
+8.63%
Follow CRVS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(35.82%) | (32.60%) | (30.46%) | (35.43%) | |
| (21.65%) | (21.83%) | (28.26%) | (32.93%) | ||
ROIC |
(399.52%) | (602.85%) | (755.45%) | (352.49%) | |
Return on Tangible Assets |
(25.51%) | (31.16%) | (19.36%) | (26.01%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.42) | (0.39) | (0.49) | |
Free Cash Flow |
(32.21) | (32.97) | (35.14) | (45.23) | |
Capital Expenditures |
(0.14) | (0.17) | (0.23) | (0.70) | |
| Other line items | |||||
Cash ROIC |
(23.44%) | (27.95%) | (7.36%) | (10.27%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
2.13 | 2.15 | 0.79 | 0.82 | |
Depreciation/Fixed assets |
(5.55) | (5.64) | (3.40) | (0.52) | |
Capex/Depreciation |
0.12 | 0.14 | 0.24 | 1.60 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.42) | (0.39) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026